DKSH Transfers two China Pharma Brands to CMS
by swisscham in Engineering, Manufacturing
DKSH and China Medical System Holdings Limited (CMS), a leading pharmaceutical services provider, have signed an agreement for the transfer of Combizym and Hirudoid, two pharmaceutical brands owned and marketed by DKSH in China. CombizymÕs current market presence is almost uniquely focused on China and therefore the entire business will be handed over to CMS. Hirudoid is today marketed and distributed by DKSH on a regional basis. Here, the transaction solely comprises the purchase of Hirudoid products in mainland China. DKSH will continue to expand the brand outside of China and to source the products for the Chinese market. The Chinese pharmaceutical market is one of the worldÕs biggest, yet highly fragmented and competitive. The transaction allows DKSH to consistently implement its China strategy for sustainable, profitable growth as a Market Expansion Services provider in selective niches.